rEsuLts Patients with stable CAD carrying the variant allele -765 C allele had increased urinary excretion of PGE 2 meta bolite and higher serum levels of sCD163 than patients carrying the -765 G allele. In contrast to these clinical findings, in vitro functional studies demonstrated that the -765 C variant allele was less responsive than -765 G allele to a wide range of COX-2 inducers.
concLusIons A substantial part of total PGE 2 bio synthesis is contributed by activated monocytes/ macrophages in stable CAD. The exact mechanism of activation of this pathway in CAD requires further research because of the conflicting results on COX-2 -765 G>C polymorphism provided by clinical studies and in vitro functional studies.
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coronary heart disease, cyclooxygenase-2, inflammatory response, promoter polymorphism, prostaglandin E 2 December 31, 2006. A total of 1386 patients from southern Poland, with a suspicion of coronary artery disease (CAD), underwent invasive evaluation. Out of 974 subjects with angiographically proven CAD (coronary stenosis >70% in diameter), stable angina pectoris was diagnosed in 628 (64.5%) subjects. Of these, we recruited 274 individuals, who had regularly received aspirin at a dose of 150 mg/d, for at least 7 days before coronary angiography. The remaining 354 patients took aspirin irregularly, or at doses other than 150 mg/d, or did not receive aspirin. In the group of 274 patients, the following exclusion criteria were used: acute inflammatory and/or infectious diseases (12 patients), chronic inflammatory diseases other than atherothrombosis and/ or chronic use of nonsteroidal anti-inflammatory drugs other than aspirin (49 patients), bronchial asthma (9 patients), auto immune disorders or malignancies (3 patients), therapy with other drugs that affect hemo stasis (29 patients), renal or liver insufficiency (13 patients), refusal to give consent (25 patients), disregard for appointments (lack of cooperation) (7 patients), coexisting acute psychosis (1 patient), alcoholism, or drug abuse (3 patients).
The study population ultimately comprised 123 white patients (37 females, 86 males), aged 39 to 86 years (mean 62.6 ±11.2). Their demographic, clinical, and genetic characteristics are presented in the tAbLE. They were on chronic therapy with aspirin (100%), statins (88%), angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (87%), β blockers (78%), nitrates (69%), calcium antagonists (48%), and diuretics (42%). The control group comprised 128 healthy subjects (59 women, 69 men), aged 24 to 70 years (mean age 41.5 ±15.8 years). These
The COX-2 gene shows a marked variability, and more than 170 single nucleotide polymorphisms (SNPs) were listed in the NCBI/SNP database (National Center for Biotechnology Information SNP database). So far, a functional significance has been reported only for a minority of these SNPs. A variant in the COX-2 promoter, -765 G>C (rs20 417), has been particularly inter esting. It is located within a putative binding site for Spl, considered to be a positive activator of COX-2 transcription. 6 Variable pharmacodynamic responses of this functional polymorphism were seen in COX-2 expression pattern and after ex vivo stimulation with lipopolysaccharide (LPS). 7-9 A comparison of COX-2 promoter constructs revealed that the -765 C allele had a lower activity than -765 G allele when transfected into human cervical epithelium cancer (HeLa) cells, 6 but opposite results were obtained when transfection was conducted on human neural cells.
7 Patients carrying -765 C allele were reported to have a lower risk of myocardial infarction and ischemic stroke. 8, 9 However, these clinical findings have not been confirmed by other studies. 10, 11 We hypothesized that in patients with coronary heart disease the -765 G>C COX-2 polymorphism might influence the capacity of activated monocytes/macrophages to synthesize PGE 2 , and this would be reflected by systemic PGE 2 production and associated with a specific marker of monocyte activation. We also designed experiments to directly determine the activity of the 2 promoter variants, using fluorescent protein gene expression in the transfected cells.
PAtIEnts And mEthods subjects A prospective, observational, cross-sectional study started on January 1, 2005 and was completed on 14 (25) 6 (10.7)
(8.9)
a mean values ± standard deviation Abbreviations: BMI -body mass index, CAD -coronary artery disease, HDL -high-density lipoprotein, LDL -low-density lipoprotein, PADperipheral arterial disease, PCI -percutaneous coronary inter vention, TIA -transient ischemic attack
Transfections were performed on 3-4 million cells using electroporation procedure (BioRad gene pulser, Carlsbad, United States). The next day, regular medium was restituted and 500,000 cells were aliquoted into 6-well plate for stimulation experiments. Transformed cells were studied 48 h after transfection experiments using Coulter Epics XL flow cytometer. Stably transfected cells were selected using geneticin (G-418, Sigma, Saint Louis, United States) at a concentration of 1 mg/ml. In these experiments no GFP marker cotransfection was used, and red-channel fluorescence was compared with mock transfected cells in order to compensate for auto fluorescence bias. Several inducers of COX-2 expression were tested: bacterial LPS (Sigma, Saint Louis, United States, 0.1 μg/ml), inter leukin 1β (IL-1β) (R&D Systems, Minneapolis, United States, 10 ng/ml), estradiol (Sigma, 10 nM and 100 nM), 22(R)--hydroxycholesterol (0.2 and 20 μM) and T0 901 317 (oxysterol agonist 0.25 and 2.5 μM, Cayman Chemical Co.).
statistical analysis Urinary excretion of tetranor-PGE-M, 6-keto-PGF 1α and serum levels of sCD163 were reported as arithmetic mean with 95% confidence inter val (CI). Statistical tests were performed on log-transformed data to stabilize the variance. Comparisons between genotype classes of COX-2 promoter polymorphism were performed using ANOVA. Analyses of the mean fluorescence intensity were made using geometric means of relative fluorescence units and repeated measurement ANOVA tests, with post-hoc comparisons. Cytofluorimetric data on stable transfected adherent THP-1 cells were compared using a mock transfected reference sample and expressed also as percentage of positive cells. P <0.05 was considered statistically significant. rEsuLts Genotyping A rare -765 C variant COX-2 allele was found in 2 homo zygous (1.6%) and 41 heterozygous (33.3%) CAD patients, the remaining 80 patients (65%) were homo zygous for the wild type G allele. Genotype frequencies of -765 G>C polymorphism are summarized in the tAbLE. The minor allele frequency of this polymorphism was 18.29% and the genotypes were in Hardy-Weinberg equilibrium. No association was found between the genotypes and coronary vessel involvement as evaluated by coronary angiography (data not shown).
In the control group, the -765 C allele was found in 4 homo zygous (3.1%) and 33 heterozygous (25.8%) subjects; the remaining 91 subjects (71.1%) were homo zygous for the G allele. Minor allele frequency was 16.01% and the genotypes were in Hardy-Weinberg equilibrium. The distribution of genotypes in the 2 studied groups did not differ significantly.
Inflammatory bio markers
The results of inflammatory bio markers measurements are presented subjects were randomly sampled from the registers provided by the local authorities of Kraków.
All patients gave written informed consent to participate in the study. The study protocol complied with the Helsinki Declaration and was approved by the University Ethical Committee.
Genotyping Common COX2 -765 G>C polymorphism was genotyped using genomic DNA, isolated from peripheral blood as described previously. 12 measurement of urinary tetranor-PGE-m and 6-keto-PGF 1α Urinary concentration of 9,15--dioxo-11α-hydroxy-2,3,4,5-tetranor-prostane--1,20-dioic acid (tetranor-PGE-M) was measured by gas chromatography/mass spectro metry using inter nal deuterated standard. 13 Urinary tetranor-PGE-M was expressed as nanograms per mg of urinary creatinine, after recalculation for a deuterated compound to compensate the loss during preparation. Urinary level of 6-keto-PGF 1α , one of the prostacyclin end meta bolites, was measured in duplicate using a commercial enzyme-linked immunoassay (6-keto-PGF 1α ELISA, Cayman Chemical Co., Ann Arbor, United States) and expressed as nanograms per mg of urinary creatinine.
measurement of serum cd163 concentration
The serum levels of soluble CD163 (sCD163) antigen were measured in duplicate using a commercial ELISA (Cedarlane Laboratories, Hornby, Canada) in 44 patients with stable CAD matched for sex and age, but contrasted for -765 G>C polymorphism of COX-2 gene. Serum samples were diluted 1:200 and processed according to the manufacturer's instructions. The intra-assay coefficient of variation was 8%. dIscussIon Distribution of the COX-2 -765 G>C genotypes observed in control subjects is in line with the results of our previous study on the Polish population 12 and with other studies on the white European and American populations. In all of these studies, the minor C allele frequency ranged from 0.15 to 0.18.
10,11,14,15 A higher frequency of the variant allele was reported only in Italian 8 and Spanish 16 controls with the minor C allele frequency of 0.25. A higher frequency of C variant allele, ranging from 0.32 to 0.42 was observed in African Americans. 11, 15 It has been reported that -765 C allele might protect against myocardial infarction.
8 C allele was in The range of sCD163 levels varied from 0.63 to 14.4 μg/ml with the mean 4.59 (3.35-5.28, 95% CI). In patients carrying -765 C allele of COX-2 gene, serum levels of sCD163 were higher than in GG homo zygotes (5.41 vs. 3.37, P = 0.023). Several clinical para meters, i.e., age, total white cell blood count, monocyte and neutrophil count, total serum cholesterol, low-or high-density lipoprotein cholesterol, and C-reactive protein (CRP) were tested as covariant to the ANOVA model based on genotype classes. Only total serum cholesterol significantly contributed to the model (P = 0.045) and improved its goodness of fit (P = 0.015). Serum sCD163 correlated with urinary tetranor-PG-M (least median of squares robust regression R 2 = 0.79).
In vitro studies Using each investigated cell line, a similar regulatory property of allelic variants of -765
G>C polymorphism was observed (FIGurE 2) . It consisted in the higher level of transgene expression for the wild type -765 G allele, by 49.0 ±25.1% on average. The highest overexpression was noted in THP-1 cells growing in suspension (monocyte model -80.1%), the lowest was in the same cells but growing adherently (macrophage model -14.5%).
These differences were significant for THP-1 cells cultured in suspension, the same cells differentiated into adherent macrophages and is associated with higher PGE 2 bio synthesis than the presence of G allele alone. We used the specific and highly sensitive method for measurement of stable urinary PGE 2 meta bolite considered to reflect the systemic PGE 2 production. In the studied patients, as observed in healthy subjects, tetranor-PGE-M excretion was higher in men (9.19 ng/mg creatinine; 7.28-11.1, 95% CI) than in women (7.59 ng/mg creatinine; 3.94-11.24, 95% CI; P = 0.1). Urinary excretion of 6-keto-PGF 1α , one of the inactivation products of PGI 2 , was not influenced by the COX-2 polymorphism. However, in contrast to tetranor-PGE-M, 6-keto-PGF 1α predominantly reflects renal biosynthesis of prostacyclin. 17 We suggest that a large part of tetranor-PGE-M, which we studied, could be generated by stimulated monocytes/macrophages. Monocyte-derived macrophages are involved in all stages of atherosclerotic lesion development.
18,19 PGE 2 is a predominant prostanoid synthesized via monocytic COX-2. Its production by stimulated blood monocytes is associated with the onset and progression of carotid atherosclerosis. Exclusively monocytes/macrophages express on their surface CD163, a 130-kDa hemo globin scavenger receptor. CD163 + macrophages are present in atherosclerotic lesions and several lines of evidence link them to the development of atherosclerosis. sCD163 is a normal constituent of plasma and is generated by the proteolytic cleavage of CD163 at the cell surface. Its plasma levels increase significantly with CAD progression. 19 Importantly, sCD163 has been found to be a predictor of CAD extension, independently of the conventional risk factors.
19 In all our patients with CAD, this novel plasma marker of coronary atherosclerotic burden correlated significantly with tetranor-PGE-M. Moreover, sCD163 levels were greater in patients carrying -765 C allele by 60.5% compared with allele G homo zygotes.
In vitro experiments, in which we tested the expression pattern of the transgene, engineered to produce red-fluorescence protein under also thought to be associated with lower levels of inflammatory markers such as CRP and IL-6 in cardiac, cerebrovascular, and hypercholesterolemic patients. 6, 16 In contrast to these associations, we found no evidence for risk of prior myocardial infarction due to the presence of the variant COX-2 allele. Hegener et al., 10 Huuskonen et al., 14 and Lee et al. 15 reached similar conclusions. Furthermore, Kushaka et al. 11 has recently reported that -765 C allele is in fact a risk factor for stroke in African Americans. Observations from Finland 14 also suggest that C allele is a risk factor for CAD. Thus, middle-aged Finnish men who died suddenly and carried the minor frequency C allele had larger areas of complicated coronary lesions and a higher number of coronary arteries with over 50% stenosis, compared with men with GG genotypes.
Our results indicate that the COX-2 promoter polymorphism -765 G>C is associated with systemic production of PGE 2 in patients with stable coronary artery disease. The presence of C allele the control of either allelic variant of COX-2 regulatory region, were generally in line with the original report by Papa fili et al. 6 We confirmed higher COX-2 induction in HeLa cells stimulated with bacterial LPS, conditions under which -765 G allele showed increased expression. Using cell lines of endothelial origin (HMEC-1) and of monocyte/macrophage lineage (MonoMac and THP-1), we replicated this finding across a spectrum of bio logical compounds known to induce COX-2 expression. Despite numerous experiments, including oxysterols hinted by contribution of total serum cholesterol to the systemic PGE 2 biosynthesis, our cellular models seem far from a natural human setting, because most of COX-2 induction that we observed was still tenfold less, as compared to ex vivo experiments on blood-derived monocytes. 12 Thus, established cell lines are missing an important factor, which was responsible for our previous observation on a spectacular overproduction of PGE 2 in blood-derived monocytes in subjects carrying -765 C allele. In a recent report on COX-2 induction in adherent macrophages, 20 one of these humoral factors was identified as transforming growth factor-β, released by activated blood platelets. Increased activity of COX-2 in macrophages results in overproduction of prostanoids, which act not only on the systemic level but also in auto crine or paracrine manner. As the constructs we tested produced an inert mar ker protein instead COX-2, no prostanoid feedback was included in our model. Using peripheral blood monocytes, Skarke et al. 21 observed increased abundance of COX-2 transcripts in -765 CC subjects following LPS stimulation, a pattern which required a prolonged cell activation. In summary, we observed that CAD patients carrying a genetic variant of COX-2 -765 C produce greater amounts of PGE 2 , and this overproduction is accompanied by enhanced serum levels of sCD163, a marker of macrophage/monophage activation. In vitro, the variant -765 C allele is less responsive to a wide range of cyclooxygenase inducers than -765 G allele, probably because this model lacks a pivotal factor that activates macrophages within the arterial wall.
